Cell processing technologies market seen reaching $9.24B by 2030

The Business Research Company says the cell processing technologies market will grow from $4.89 billion in 2025 to $9.24 billion by 2030, supported by cell therapy commercialization, automation and personalized medicine demand. North America remained the largest regional market in 2025.

Why it matters: - Cell processing technologies sit at the center of cell therapy, regenerative medicine and personalized medicine. - The market’s projected growth points to higher demand for tools that can isolate, manipulate, expand and prepare living cells at scale. - The forecast signals more investment in automation, quality control and closed-system handling as clinical and commercial use expands.

What happened: - The Business Research Company released its Cell Processing Technologies Global Market Report 2026 with market size, trend and forecast data through 2035. - The report values the market at $4.89 billion in 2025 and $5.56 billion in 2026. - The market is forecast to reach $9.24 billion by 2030. - The report projects a 13.7% CAGR from 2025 to 2026 and a 13.5% CAGR through 2030. - North America was the largest regional market in 2025.

The details: - Past growth was driven by cell-based research, broader use of cell culture methods, regenerative medicine studies, sophisticated laboratory instruments and more funding for academic and clinical research. - Future growth is expected to come from commercialization of cell therapies, higher demand for scalable manufacturing, broader use in personalized medicine, more investment in bioprocessing automation and tighter regulatory attention on cell processing standards. - Key trends include more automated systems, greater use of closed-system cell handling, digital monitoring tools, single-use consumables, stronger cell viability controls and stricter quality control. - Cell processing technologies cover techniques and equipment used to preserve cell viability, functionality and safety in research, diagnostics and therapies. - The global analysis also includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report’s 2026 edition includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend graphics. - The report offers a free sample and the full report online: Download a free sample and View the full report.

Between the lines: - Personalized medicine is a major demand driver because it depends on precise preparation of patient-specific cells. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 26 new personalized medicines in 2023, nearly double the 12 approvals in 2022. - That approval jump suggests continued momentum for therapies that rely on advanced cell processing methods. - The report’s emphasis on automation and closed systems suggests the market is moving toward higher-throughput, more standardized manufacturing.

What's next: - The market is expected to keep expanding as cell therapies move further into commercialization. - Suppliers will likely compete on automation, digital monitoring, consumables and process consistency. - Regulatory scrutiny around standards and quality control is likely to shape product development and manufacturing practices. - More market intelligence tools and forecasting updates are expected in the report series as the sector evolves.

The bottom line: - Cell processing technologies are moving from a research support market to a core enabler of commercial cell therapies and personalized medicine.